Tesamorelin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
=== Deconvolution of libraries cleaved from the solid support === If the synthesized molecules of a combinatorial library are cleaved from the solid support, a soluble mixture forms. In such solution, millions of different compounds may be found. When this synthetic method was developed, it first seemed impossible to identify the molecules, and to find molecules with useful properties. Strategies for identification of the useful components have been developed, however, to solve this problem. All these strategies are based on synthesis and testing of partial libraries. An early iterative strategy was devised by Furka in 1982. The method was later independently published by Erb et al. under the name "Recursive deconvolution"
Alcohol can have analgesic (pain-relieving) effects, which is why some people with chronic pain turn to alcohol to self-medicate and try to alleviate their physical discomfort. People with social anxiety disorder commonly self-medicate with alcohol to overcome their highly set inhibitions. However, self-medicating excessively for prolonged periods of time with alcohol often makes the symptoms of anxiety or depression worse. This is believed to occur as a result of the changes in brain chemistry from long-term use. A 2023 systematic review highlights the non-addictive use of alcohol for managing developmental issues, personality traits, and psychiatric symptoms, emphasizing the need for informed, harm-controlled approaches to alcohol consumption within a personalized health policy framework.
=== Americas === Brazil introduced universal BCG immunization in 1967–1968, and the practice continues to this day. According to Brazilian law, BCG is also given to people who live together with patients with leprosy. Canadian Indigenous communities receive the BCG vaccine, and in the province of Quebec the vaccine was offered to children until the mid-1970s. Most countries in Central and South America have universal BCG immunizations, as does Mexico. The United States has never used mass immunization of BCG due to the rarity of tuberculosis in the US, relying instead on the detection and treatment of latent tuberculosis.
Sources: en.wikipedia.org
On the same day, National Assembly president Jorge Rodríguez issued a separate communiqué confirming the start of the joint agenda, framing it as part of a national unity effort following the earthquakes and emphasizing reconstruction and social stability without explicitly referring to electoral reforms. In September 2026, Interior minister Diosdado Cabello hinted 2028 as a possible year for election day, stating "I believe (the opposition) they'll go for 2028; whenever that is, the United Socialist Party of Venezuela will be there, ready to win."
In 2014, Guinness released Guinness Blonde, a lager brewed in Latrobe, Pennsylvania using a combination of Guinness yeast and American ingredients. When Guinness opened their new brewery in Baltimore, Maryland in August 2018 they recreated "Blonde" to "Baltimore Blonde" by adjusting the grain mixture and adding Citra for a citrus flavour and removed the Mosaic hops. Guinness released a lager in 2015 called Hop House 13. It was withdrawn from sale in the UK in May 2021, following poor sales, but remains on sale in Ireland. In 2020, Guinness announced the introduction of a zero alcohol canned stout, Guinness 0.0. It was withdrawn from sale almost immediately after launch, due to contamination. It was relaunched in 2021 starting with pubs in mid July with cans following in late August. In September 2021, Guinness Nitrosurge was released in pint sized cans which contain no widget. Similar to the Surger, nitrogen is activated using ultrasonic frequencies. Nitrosurge uses a special device attached to the top of the can which activates the nitrogen as it is being poured.
The IDF said that one in five rockets launched by Hezbollah had landed in Lebanese territory and published an infographic showing failed rocket launches into Israel. On 16 December, a soldier from the IDF's 129th Battalion was killed by a Hezbollah drone strike near Margaliot, which also caused a fire in a building. Two other soldiers were injured. Another drone was shot down by the IDF, which also responded to the infiltrations by shelling targets. The IAF later hit several Hezbollah targets inside Lebanon, including rocket launch sites and military infrastructure. On 22 December, two IDF soldiers of the 188th Armored Brigade were killed by a Hezbollah rocket attack in the Shtula area. On the morning of 23 December, IDF aircraft bombed a house in Kfar Kila and intense artillery fire also took place on the outskirts of Deir Mimas The IDF conducted a raid near a UNIFL center along the Khardali River. An Al-Manar cameraman was injured in the eye after an IDF attack on a road in the al-Khardali area where correspondents of MTV and the state-owned National News Agency were also passing. Hezbollah announced that two of their members were killed on that day. On 24 December, senior IRGC general Razi Mousavi was killed by an Israeli airstrike in Damascus. On 26 December, a Hezbollah anti-tank missile hit St. Mary's Greek Orthodox Church in Iqrit, northern Israel. A civilian suffered serious injuries, and when IDF responders arrived at the scene, another missile was fired, injuring nine soldiers.
Sources: en.wikipedia.org
SEP findings do not by themselves lead to a specific diagnosis, and organic diseases cannot necessarily be excluded with normal SEP findings. Findings must be interpreted in the context of the patient’s clinical presentation. Evaluating the peripheral responses with SEPs could contribute to the diagnosis of peripheral nerve damage. Furthermore, SEPs could be abnormal in different pathologies such as multiple sclerosis (MS), hereditary spinocerebellar degenerations, hereditary spastic paraplegia, AIDS and vitamin B12 or vitamin E deficiency. In patients with MS, evoked potential findings often complement findings on MRI. In the acute stage after a traumatic spinal injury or brain trauma, the absence of SEP responses do not correlate with prognosis. However, an early return to normal or preserved cortical responses in the subacute stage correlate with a positive outcome. SEPs can evaluate subcortical and cortical function in comatose patients and are less sensitive to sedative drugs than EEG. SEP´s and BAEP´s together are tools to assist in the confirmation of brain death in comatose patients
1-DeoxySLs has a similar pattern to sphingolipids during de novo synthesis. The reaction is catalyzed by the enzyme serine palmitoyltransferase (SPT) but instead of condensing palmitoyl-CoA and L-serine, the amino acid substrate is replaced by L-alanina or L-glycine. This atypical sphingolipids are formed as the result of a mutated SPT (SPTLC1/SPTLC2) with alternative activities. It has also produced by wild-type of SPT under unfavorable conditions where the synthesis of L-serine is diminished and / or the biosynthesis of alanine and glycine is too high. The result of the reaction with L-alanine forms 1-deoxysphinganine (1-deoxySA; m18:0), while the use of glycerin forms 1-deoxymethylsphinganine (1-deoxymethylSA; m17:0). Both molecules are 1-deoxySLs.
== Bulk properties == Thorium is a moderately soft, paramagnetic, bright silvery radioactive actinide metal that can be bent or shaped. In the periodic table, it lies to the right of actinium, to the left of protactinium, and below cerium. Pure thorium is very ductile and, as normal for metals, can be cold-rolled, swaged, and drawn. At room temperature, thorium metal has a face-centred cubic crystal structure; it has two other forms, one at high temperature (over 1360 °C; body-centred cubic) and one at high pressure (around 100 GPa; body-centred tetragonal). Thorium metal has a bulk modulus (a measure of resistance to compression of a material) of 54 GPa, about the same as tin's (58.2 GPa). Aluminium's is 75.2 GPa; copper's is 137.8 GPa; and mild steel's is 160–169 GPa. Thorium is about as hard as soft steel, so when heated it can be rolled into sheets and pulled into wire. Thorium is nearly half as dense as uranium and plutonium and is harder than both. Thorium has a magnetic susceptibility of 0.412 × 4π × 10−9 m3⋅kg−1 at room temperature. This susceptibility is mostly temperature-independent, however impurities and dopants can affect this value. It becomes superconductive below 1.4 K. Thorium's melting point of 1750 °C is above both those of actinium (1227 °C) and protactinium (1568 °C).
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.